title: Successes and Challenges of PARP Inhibitors in Cancer Therapy.
authors.affiliation: Office of Hematology and Oncology Products (OHOP), Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration , Silver Spring, MD , USA.
authors.forename: Tiffany K
authors.initials: TK
authors.lastname: Ricks
authors.affiliation: Office of Hematology and Oncology Products (OHOP), Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration , Silver Spring, MD , USA.
authors.forename: Haw-Jyh
authors.initials: HJ
authors.lastname: Chiu
authors.affiliation: Office of Hematology and Oncology Products (OHOP), Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration , Silver Spring, MD , USA.
authors.forename: Gwynn
authors.initials: G
authors.lastname: Ison
authors.affiliation: Office of Hematology and Oncology Products (OHOP), Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration , Silver Spring, MD , USA.
authors.forename: Geoffrey
authors.initials: G
authors.lastname: Kim
authors.affiliation: Office of Hematology and Oncology Products (OHOP), Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration , Silver Spring, MD , USA.
authors.forename: Amy E
authors.initials: AE
authors.lastname: McKee
authors.affiliation: Office of Hematology and Oncology Products (OHOP), Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration , Silver Spring, MD , USA.
authors.forename: Paul
authors.initials: P
authors.lastname: Kluetz
authors.affiliation: Office of Hematology and Oncology Products (OHOP), Office of New Drugs (OND), Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration , Silver Spring, MD , USA.
authors.forename: Richard
authors.initials: R
authors.lastname: Pazdur
keywords: BRCA1; BRCA2; PARP inhibitor; cancer; drug resistance; homologous recombination